- Drug Pipelines
- April 2024
- 60 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- July 2022
- 193 Pages
Global
From €5317EUR$5,500USD£4,567GBP
- Report
- January 2022
- 60 Pages
Global
From €3819EUR$3,950USD£3,280GBP
- Report
- August 2022
Global
From €764EUR$790USD£656GBP
- Report
- November 2022
- 120 Pages
Global
From €2417EUR$2,500USD£2,076GBP
- Drug Pipelines
- June 2020
- 84 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- October 2023
- 122 Pages
Global
From €3500EUR$3,878USD£3,112GBP
- Report
- May 2022
- 91 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- December 2022
- 69 Pages
Global
From €1934EUR$2,000USD£1,661GBP
- Report
- May 2023
- 160 Pages
Global
From €5800EUR$5,999USD£4,982GBP
The Sexual Dysfunction Drug market is a subset of the Sexual and Reproductive Health Drugs market. It includes drugs used to treat conditions such as erectile dysfunction, premature ejaculation, and hypoactive sexual desire disorder. These drugs are typically prescribed by a doctor and can be taken orally, injected, or applied topically. They work by increasing blood flow to the penis, increasing sensitivity, and improving sexual arousal.
The Sexual Dysfunction Drug market is highly competitive, with many companies offering similar products. Some of the major players in the market include Pfizer, Eli Lilly, Bayer, and GlaxoSmithKline. Other companies include Merck, Novartis, and AstraZeneca. Show Less Read more
